Back to Search

MARK BOYTIM, M.D.

M.D.

Specialist

NPI: 1104857697Individual

Specialties, Licenses & Credentials

SpecialistPrimary

Specialist

Code: 174400000X

C1-0003326(DE)

Research & Publications (5)

A human class II MHC-derived peptide antagonizes phosphatidylinositol 3-kinase to block IL-2 signaling.
PMID 10811852·J Clin Invest·2000
8-other
A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
PMID 19499186·Invest New Drugs·2010
3-trial
Radiofrequency tonsil reduction.
PMID 11587617·Arch Otolaryngol Head Neck Surg·2001
8-other
Pharmacologic rationale for anesthetic agents in ambulatory practice.
PMID 11740778·J Perianesth Nurs·2001
6-review
Proliferating cell nuclear antigen as the cell cycle sensor for an HLA-derived peptide blocking T cell proliferation.
PMID 10843669·J Immunol·2000
8-other

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
701 SAVANNAH RD, SUITE B
LEWES, DE 19958

Location

Practice Location

701 SAVANNAH RD, LEWES, DE
(302) 645-2805

Quick Facts

NPI
1104857697
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
1
Locations
1
Publications
5

Are you this provider?

Claim Your Profile